58-year-old man with systemic sclerosis and dyspnea
A 58-year-old man with a 10-year history of limited cutaneous systemic sclerosis, characterized by Raynaud phenomenon and positive anti-centromere antibodies, presents for follow-up. He is a retired construction worker and reports a 6-month history of progressive fatigue and shortness of breath when playing with his grandchildren. He denies chest pain, cough, or wheezing. His medications include amlodipine for hypertension and omeprazole for GERD. Physical examination reveals a heart rate of 88/min, blood pressure of 134/82 mm Hg, and oxygen saturation of 96% on ambient air. The cardiac examination is notable for a prominent P2 component of the second heart sound. There is no peripheral edema. Pulmonary function tests show an FEV1/FVC ratio of 82%, FVC of 95% predicted, but a DLCO of 45% predicted. An echocardiogram demonstrates a normal left ventricular size and function, but shows right ventricular enlargement and an estimated right ventricular systolic pressure of 60 mm Hg. Which of the following is the most appropriate next step in management?
See the answer and explanation below:
Post-Call Recovery Reads
Finished your notes? Time to swap the pager for a crown. Kingdoms of Silent Sorrows is the ultimate 'brain-break', a high-stakes fantasy featuring a Fae princess, a Vampire king, and an enemies-to-lovers arc that will actually make you forget about your rounding list. No p-values, just fated mates and forbidden magic.
View on AmazonThe Correct Answer
A
Explanation
Clinical Pearl:
An isolated reduction in the diffusing capacity for carbon monoxide (DLCO) in a patient with a connective tissue disease, such as systemic sclerosis, should raise strong suspicion for pulmonary arterial hypertension. Echocardiography is the primary screening tool, but right heart catheterization is the gold standard required for diagnosis.
Explanation:
This patient's presentation, including progressive dyspnea in the setting of limited systemic sclerosis, an isolated reduction in DLCO on pulmonary function testing, and echocardiographic findings of right ventricular pressure overload, is highly suggestive of WHO Group 1 pulmonary arterial hypertension (PAH). According to current society guidelines, right heart catheterization is the mandatory next step to confirm the diagnosis. This procedure provides direct measurement of pulmonary artery pressures, pulmonary capillary wedge pressure (to exclude left-sided heart disease), and cardiac output, which are required to calculate the pulmonary vascular resistance and definitively establish the diagnosis before initiating targeted therapy. Obtaining a high-resolution CT of the chest would be appropriate to evaluate for interstitial lung disease, but this patient's normal lung volumes make significant parenchymal disease an unlikely cause of his findings. Initiating therapy with sildenafil is premature and inappropriate without hemodynamic confirmation of PAH. A ventilation-perfusion scan is part of the standard workup to exclude chronic thromboembolic pulmonary hypertension (WHO Group 4), but it does not confirm the diagnosis of PAH or provide the necessary hemodynamic data for management. A six-minute walk test is used to assess functional status and response to treatment, not to establish a diagnosis.
See you tomorrow morning!